Polyclonal and monoclonal antibodies for induction therapy in #KidneyTransplant recipients https://t.co/oO4XQpsAjd https://t.co/C00oGjheGf

@drmjkulkarni @HecmagsMD @hswapnil @VijayKher8 @manirath @NephJC @arvindcanchi @SreejithDr @raja_1980 @Nair_Sanj @vskeskar https://t.co/dR2pKj8xva recipients. Less quoted review but that's what most of us seems to be following. Sorry Up

RT @KFSHRC_Research: Polyclonal and monoclonal antibodies for induction therapy in #KidneyTransplant recipients https://t.co/BsZ2EM5Uxy htt…

RT @KFSHRC_Research: Polyclonal and monoclonal antibodies for induction therapy in #KidneyTransplant recipients https://t.co/BsZ2EM5Uxy htt…

RT @KFSHRC_Research: Polyclonal and monoclonal antibodies for induction therapy in #KidneyTransplant recipients https://t.co/BsZ2EM5Uxy htt…

Polyclonal and monoclonal antibodies for induction therapy in #KidneyTransplant recipients https://t.co/BsZ2EM5Uxy https://t.co/BWZOZ8CcFE

RT @TrlsChangeLives: #CochraneDaily 99 studies of polyclonal & monoclonal a'bodies in kidney transplantation new @CochraneLibrary review ht…

Polyclonal and monoclonal antibodies for induction therapy in #kidneytransplant recipients https://t.co/d5wfOBl0mp https://t.co/4mRL0UmuzU

#CochraneDaily 99 studies of polyclonal & monoclonal a'bodies in kidney transplantation new @CochraneLibrary review https://t.co/J5wkYg3MMG

RT @kidneydoc101: Interesting...feminist perspective would be to chose regimen that avoids MMF for anyone hoping to conceive. Not factored…

RT @kidneydoc101: Interesting...feminist perspective would be to chose regimen that avoids MMF for anyone hoping to conceive. Not factored…

RT @kidneydoc101: Interesting...feminist perspective would be to chose regimen that avoids MMF for anyone hoping to conceive. Not factored…

Interesting...feminist perspective would be to chose regimen that avoids MMF for anyone hoping to conceive. Not factored here. https://t.co/8CATv7LrLe

#Alemtuzumab + ST minimisation prevents #acuterejection at 1 year 🆚 rATG #kidneytransplant #gated @CochraneKidney https://t.co/Ifr0vdT7oC

RT @CochraneKidney: New Review: ATG reduces acute rejection and increases CMV infection, thrombocytopenia and leucopenia in #kidney Tx http…

RT @CochraneKidney: New Review: Alemtuzumab + steroid minimisation prevents acute rejection at 1 year compared to ATG in #kidney Tx https:/…

RT @CochraneKidney: New Review: Alemtuzumab + steroid minimisation prevents acute rejection at 1 year compared to ATG in #kidney Tx https:/…

RT @CochraneKidney: New Review: ATG reduces acute rejection and increases CMV infection, thrombocytopenia and leucopenia in #kidney Tx http…

RT @CochraneKidney: New Review: Alemtuzumab + steroid minimisation prevents acute rejection at 1 year compared to ATG in #kidney Tx https:/…

RT @CochraneKidney: New Review: Alemtuzumab + steroid minimisation prevents acute rejection at 1 year compared to ATG in #kidney Tx https:/…

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant-Cochrane meta analysis https://t.co/Nps8KGrPdl

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients https://t.co/b87TwTDSSP

RT @CochraneKidney: New Review: Alemtuzumab + steroid minimisation prevents acute rejection at 1 year compared to ATG in #kidney Tx https:/…

RT @CochraneKidney: New Review: ATG reduces acute rejection and increases CMV infection, thrombocytopenia and leucopenia in #kidney Tx http…

RT @CochraneKidney: New Review: ATG reduces acute rejection and increases CMV infection, thrombocytopenia and leucopenia in #kidney Tx http…

New Review: Alemtuzumab + steroid minimisation prevents acute rejection at 1 year compared to ATG in #kidney Tx https://t.co/wL2i9oUkKu

New Review: ATG reduces acute rejection and increases CMV infection, thrombocytopenia and leucopenia in #kidney Tx https://t.co/wL2i9oCJlU